"Sustainability can deliver significant economic benefits." Dennis Brandl of BR&L Consulting demonstrated how green chemistry can help manufacturers comply with regulations as well as enable productivity, profitability and other business goals.
In practical terms, Brandl reported that Pfizer recently redesigned its sertraline (Zoloft) commercial process to eliminate the number and volume of solvents used and reduce titanium dioxide waste and HCl waste. "The new process uses 26 liters/kg of product versus the original 98 liters/kg used in its first commercial route," said Brandl. "Pfizer received the 2002 Presidential Green Chemistry Award for Greener Synthetic Pathways for this redesign."
Similarly, he added that Pfizer improved its sildenafil manufacturing process by reducing solvent usage of 22 liters/kg to 7 liters/kg by improving the synthesis route and by implementing more efficient solvent recovery. As a result, Pfizer received the U.K. Green Technology award in 2003 for these efforts by improving its e-factor to a 6 rating.
Likewise, because Pfizer's atoravastin calcium (Lipitor) product uses a key hydroxy nitrile (HN) building block, Brandl explained that its Codexis partner devised three bioengineered enzymes to improve volumetric productivity by 100 fold of the reduction reaction and improve its cyanation reaction by 4,000 fold over the HN process. "This resulted in a new process with fewer unit operations, improved yield and worker safety, and reduced formation of byproducts, waste and equipment usage," said Brandl. "Codexis received the 2006 Presidential Green Chemistry award for Greener Reaction Conditions."
Â
Finally, Pfizer developed a new enzymatic route for manufacturing its gabapentin (Lyrica) product. "It eliminated organic solvents from three reaction steps, while increasing the overall yield. This also minimized waste significantly," he said.
To develop and achieve some of these green chemistry and sustainability gains, Brandl stressed that users must examine both their product development and their process development, and then consider the sustainability factors associated with those products and processes, such as waste, non-renewable resources and energy. Generally, green chemistry is part of intermediate and final activity pharmaceutical ingredient (API) production steps, and the waste material issues tend to crop up during the unit dosage manufacturing and packaging steps.
"The task on the manufacturing side is how to best capture these steps. The ISA 88 batch standard defines general recipes and capturing chemical and other process steps," explained Brandl. "As a result, there are 30 to 40 basic tasks you can do in these manufacturing processes, and this gives us a library of items for which we can consider the sustainability factors and possibly add them to the process action step.
"For instance, we can look at a general recipe and then also ask about its waste and recovered material. So we're looking at what it takes to make a product and what it takes to reduce its waste at the same time," he said. "For example a typical process action report for a blending application might have numbers on weight, density, moisture and other physical characteristics, but a sustainability report on a process action will add measurements of energy use, waste and/or recovered material to the batch record." This consideration of sustainability factors also can be plugged into a general recipe model or added during other steps, such as the R&D product synthesis description, global equipment property descriptions, global material specifications and global process definition.
"In general, sustainability can deliver significant economic benefits," said Brandl. "But there also will be additional information needed, such as e-factors, material disposal costs and other waste issues. Still, general recipes will provide a good basis for manufacturing alternatives and documenting sustainability."